Immunome
IMNM • NASDAQ
Immunome is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Clay Siegall, with a market cap of $2.2B.
CEOClay Siegall
Next Earnings
Upcoming earnings announcement for Immunome
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.57
Revenue Estimate
$900.0K
Earnings History
Past 12 earnings reports for Immunome
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Q4 2025 | -$0.75Est: -$0.60 | -25.0% | -Est: $784.6K | -100.0% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.65Est: -$0.55 | -18.2% | -Est: $727.3K | -100.0% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$0.50Est: -$0.51 | +2.0% | $4.0MEst: $1.6M | +150.5% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.52Est: -$0.57 | +8.8% | $2.9MEst: $457.1K | +540.1% | 10-Q |
| Mar 19, 2025 | Q4 2024 | -$1.28Est: -$0.72 | -77.8% | $2.7MEst: $3.1M | -10.8% | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.78Est: -$0.56 | -39.3% | $2.9MEst: $2.1M | +36.6% | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$0.60Est: -$0.39 | -53.8% | $2.4MEst: $2.6M | -7.3% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.34Est: -$0.69 | +50.7% | $1.0MEst: $2.5M | -58.8% | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.15Est: -$0.28 | +46.4% | $3.8MEst: $2.1M | +84.8% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.36 | — | $3.6M | — | — |
| Aug 9, 2023 | Q2 2023 | -$0.46Est: -$0.16 | -187.5% | $4.3M | — | 10-Q |
| May 5, 2023 | Q1 2023 | -$0.35Est: $0.58 | -160.3% | $2.4M | — | — |